Europe relies on China for the rare earth elements essential in transition technologies, but it's making a late bid to end dependency.
Producer prices rose 0.5% last month, exceeding forecasts and marking the quickest pace in three months, as a sharp jump in services costs offset stable goods prices, signaling persistent inflationary pressures in the pipeline.
Deutsche Bank's 2025 net profit nearly doubled to €7.1bn, fueled by revenue gains and cost cuts across all divisions, even as German prosecutors launch a money-laundering investigation linked to the lender.
A blistering rally in gold and silver came to an abrupt halt Friday, with prices tumbling sharply as market volatility surged and analysts warned the historic run may be entering a precarious phase.
With consumer staples out of favor and a yield surpassing the S&P 500, Coca-Cola's resilient business and decades of dividend growth present a compelling case for long-term investors.
CNBC's Jim Cramer refrained from declaring a floor for Broadcom's stock amid mixed analyst sentiment and growing competition in the crucial AI semiconductor sector.
Medtronic secures a key European regulatory nod for its latest pulsed field ablation catheter while deepening its collaboration with Mindray, signaling a strategic push into high-growth areas of cardiac care and ambulatory surgery.
As the Bank of Canada holds rates steady, speculative capital is sifting through junior resource stocks. We examine three micro-caps—a driller, an explorer, and an oil hopeful—navigating unique challenges and opportunities in early 2026.
American Express reported a 10.6% year-over-year revenue increase to $17.57 billion for the fourth quarter of 2025, yet missed Wall Street's sales expectations. Earnings per share of $3.53 met analyst consensus estimates.
In its Q4 2025 letter, Greenlight Capital revealed a new position in dental distributor Henry Schein (HSIC), arguing the stock presents an opportunity for operational improvement and shareholder returns, despite recent underperformance.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
The AI-as-a-Service (AIaaS) market is witnessing significant growth, fueled by cloud innovation and corporate demand for scalable AI solutions. While data privacy remains a hurdle, the integration of generative AI and tailored platforms is accelerating adoption across industries.
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
Amid market volatility, these three companies offering yields above 4% present a compelling case for income-focused investors, backed by strategic pivots and resilient business models.
SoFi Technologies posts a sharp rise in quarterly profit, driven by record loan demand and a 78% revenue surge in its fee-generating financial services arm. The performance highlights a strategic shift as consumers flock to digital lenders for debt consolidation, while potential regulatory headwinds loom for the credit card industry.
Fresh Israeli military actions in central and southern Gaza have resulted in multiple casualties, testing the durability of a months-long, U.S.-brokered truce and hindering critical aid flows.
Lam Research capitalizes on soaring demand for AI chipmaking equipment, reporting record quarterly and annual revenue. While the company is aggressively expanding capacity to address supply chain bottlenecks, some analysts question if its valuation already reflects the AI-driven growth.
The incoming Dutch government, led by Prime Minister-designate Rob Jetten, has unveiled its policy agenda, pledging continued military and financial support for Ukraine and a commitment to enshrine higher NATO defense spending targets into law.
While major indices tread water ahead of key earnings, a segment of the market continues to buzz with activity. We examine three micro-cap companies—Hongli Group, Royalty Management, and CreateAI—whose financial profiles and strategic moves are capturing attention from investors willing to navigate the high-risk, high-reward penny stock arena.
